CN101190895B - N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 - Google Patents
N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 Download PDFInfo
- Publication number
- CN101190895B CN101190895B CN200610144236A CN200610144236A CN101190895B CN 101190895 B CN101190895 B CN 101190895B CN 200610144236 A CN200610144236 A CN 200610144236A CN 200610144236 A CN200610144236 A CN 200610144236A CN 101190895 B CN101190895 B CN 101190895B
- Authority
- CN
- China
- Prior art keywords
- tetrahydroisoquinoline
- boc
- formyl radical
- cdcl
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 78
- 150000001413 amino acids Chemical class 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 86
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 21
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 15
- BWKMGYQJPOAASG-VIFPVBQESA-N (3s)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-VIFPVBQESA-N 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 43
- -1 L-amino acid methyl ester Chemical class 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- HFPVZPNLMJDJFB-LBPRGKRZSA-N (3s)-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)CC2=C1 HFPVZPNLMJDJFB-LBPRGKRZSA-N 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 229940024606 amino acid Drugs 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 9
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 229960002885 histidine Drugs 0.000 claims description 6
- 229960003136 leucine Drugs 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- 229960002898 threonine Drugs 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical group COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 claims description 4
- 150000004702 methyl esters Chemical class 0.000 claims description 4
- 235000008729 phenylalanine Nutrition 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- SEWIYICDCVPBEW-BYPYZUCNSA-N L-glutamate methyl ester Chemical compound COC(=O)[C@@H](N)CCC(O)=O SEWIYICDCVPBEW-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 claims description 3
- ANSUDRATXSJBLY-VKHMYHEASA-N methyl (2s)-2-amino-3-hydroxypropanoate Chemical compound COC(=O)[C@@H](N)CO ANSUDRATXSJBLY-VKHMYHEASA-N 0.000 claims description 3
- CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 claims description 3
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 claims description 3
- KPNBUPJZFJCCIQ-LURJTMIESA-N methyl L-lysinate Chemical compound COC(=O)[C@@H](N)CCCCN KPNBUPJZFJCCIQ-LURJTMIESA-N 0.000 claims description 3
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- SWWBMHIMADRNIK-VKHMYHEASA-N (3s)-3-azaniumyl-4-methoxy-4-oxobutanoate Chemical class COC(=O)[C@@H]([NH3+])CC([O-])=O SWWBMHIMADRNIK-VKHMYHEASA-N 0.000 claims description 2
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 238000010931 ester hydrolysis Methods 0.000 claims description 2
- YXMMTUJDQTVJEN-WDSKDSINSA-N methyl (2s,3s)-2-amino-3-methylpentanoate Chemical class CC[C@H](C)[C@H](N)C(=O)OC YXMMTUJDQTVJEN-WDSKDSINSA-N 0.000 claims description 2
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 claims description 2
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- XWBUDPXCXXQEOU-VKHMYHEASA-N methyl (2s)-2,4-diamino-4-oxobutanoate Chemical class COC(=O)[C@@H](N)CC(N)=O XWBUDPXCXXQEOU-VKHMYHEASA-N 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract description 9
- 239000012454 non-polar solvent Substances 0.000 abstract description 5
- 239000002798 polar solvent Substances 0.000 abstract description 5
- 150000008575 L-amino acids Chemical group 0.000 abstract description 4
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 132
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 65
- 238000005160 1H NMR spectroscopy Methods 0.000 description 64
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 63
- 239000007787 solid Substances 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 11
- 229960001138 acetylsalicylic acid Drugs 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 229960005261 aspartic acid Drugs 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 239000004395 L-leucine Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000009127 Glutaminase Human genes 0.000 description 2
- 108010073324 Glutaminase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 241000304531 Allium macrostemon Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDLDXNCMJBOYJV-YFKPBYRVSA-N L-arginine, methyl ester Chemical class COC(=O)[C@@H](N)CCCN=C(N)N ZDLDXNCMJBOYJV-YFKPBYRVSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000002994 phenylalanines Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了具有抗血栓活性的通式(I)化合物(二环化合物(3S)-1,2,3,4-四氢异喹啉-3-羧酸),本发明还公开了该化合物的制备方法及其作为抗血栓剂的应用。本发明在(3S)-1,2,3,4-四氢异喹啉-3-羧酸的3位羧基上引入L-氨基酸残基,制备得到本发明通式(I)化合物。本发明化合物不仅具有较好的抗血栓活性,相对于用L-氨基酸修饰(3S)-1,2,3,4-四氢-β-咔啉-3-羧酸中所获得的一类抗血栓剂,其结构更为简单。此外,本发明通式(I)化合物不论是在极性溶剂抑或非极性溶剂中均有良好的溶解度,生物利用度高。
Description
技术领域
本发明涉及化合物,尤其涉及N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及它们抗血栓剂应用,属于生物医药领域。
背景技术
血管栓塞性疾病对心脑血管疾病的高死亡率负最重要的责任。血栓形成是血管栓塞性疾病发病的最重要的病因。寻找抗血栓药物是新药研究的热点之一。本发明人注意到,1,2,3,4-四氢-β-咔啉-3-S-羧酸是中药薤白中的一种成分,具有抗血小板聚集活性(姚新生等,中国药物化学杂志,1995,5,134)。针对1,2,3,4-四氢-β-咔啉-3-S-羧酸在极性溶剂和非极性溶剂中溶解度都不好带来的低生物利用度,本发明人通过在(3S)-1,2,3,4-四氢-β-咔啉-3-羧酸中引入L-氨基酸,获得了一类抗血栓剂,所获得的上述抗血栓剂虽然具有良好的抗血栓活性,但是由于(3S)-1,2,3,4-四氢-β-咔啉-3-羧酸结构复杂的缘故,以此为原料所制备的抗血栓剂也同样存在着结构复杂,由此带来的问题是制备工艺复杂,相应的必然会提高生产成本。如果从(3S)-1,2,3,4-四氢-β-咔啉-3-羧酸结构中去除吡咯环,一是由此得到的(3S)-1,2,3,4-四氢异喹啉-3-羧酸是否还具有抗血栓活性,显然是无法预测的,二是(3S)-1,2,3,4-四氢异喹啉-3-羧酸无论是在极性溶剂还是在非极性溶剂中,其溶解度都不好,以至生物利用度不高。
发明内容
本发明首先所要解决的技术问题是克服现有技术的不足,提供一类新的具有抗血栓活性的化合物,该化合物的结构相对更为简单,在极性溶剂和非极性溶剂中均具有良好的溶解度。
本发明首先所要解决的技术问题是通过以下技术方案来实现的:
具有抗血栓活性的通式(I)化合物,其结构式如下:
其中,AA选自Ala(丙氨酸)、Gly(甘氨酸)、Val(缬氨酸)、Phe(苯丙氨酸)、Leu(亮氨酸)、Ileu(异亮氨酸)、Trp(色氨酸)、Ser(丝氨酸)、Thr(苏氨酸)、Pro(脯氨酸)、Met(甲硫氨酸)、Asn(天冬酰氨)、Gln(谷氨酰氨)、His(组氨酸)、Lys(赖氨酸)、Asp(天冬氨酸)、Glu(谷氨酸)、Arg(精氨酸)、Tyr(酪氨酸)或Cys-Cys(半胱氨酸-半胱氨酸)。
本发明采用L-氨基酸修饰(3S)-1,2,3,4-四氢异喹啉-3-羧酸制备得到一系列新的N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸[通式(I)化合物],本发明通式(I)化合物不仅具有较好的抗血栓活性,相对于用L-氨基酸修饰(3S)-1,2,3,4-四氢-β-咔啉-3-羧酸中所获得的一类抗血栓剂,其结构更为简单。此外,本发明通式(I)化合物不论是在极性溶剂抑或非极性溶剂中均有良好的溶解度,生物利用度高。
本发明所要解决的另一个技术问题是提供一种制备通式(I)化合物的方法。
本发明所要解决的另一个技术问题是通过以下技术方案来实现的:
将L-氨基酸按照本领域常规方法引入到(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸的3位羧基上,水解并脱去保护基后,即得。
优选的,一种制备通式(I)化合物的方法,包括:
1.在浓盐酸存在下将苯丙氨酸与甲醛进行Pictet-Spengler缩合制备(3S)-1,2,3,4-四氢异喹啉-3-羧酸;
2.在(Boc)2O存在下将(3S)-1,2,3,4-四氢异喹啉-3-羧酸转化为(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸;
3.在二环己基碳二亚胺(DCC)和N-甲基吗啉存在下将(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸与L-氨基酸甲酯偶联制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸甲酯;
4.在碱溶液中将N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸甲酯水解制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸;
5.在氯化氢-乙酸乙酯溶液中将N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸脱Boc制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸。
上述制备方法中,步骤4中所述的L-氨基酸甲酯选自丙氨酸甲酯、甘氨酸甲酯、缬氨酸甲酯、苯丙氨酸甲酯、亮氨酸甲酯、异亮氨酸甲酯、色氨酸甲酯、丝氨酸甲酯、苏氨酸甲酯、脯氨酸甲酯、甲硫氨酸甲酯、天冬酰氨甲酯、谷氨酰氨甲酯、组氨酸甲酯、赖氨酸甲酯、天冬氨酸甲酯、谷氨酸甲酯、精氨酸甲酯、酪氨酸甲酯或半胱氨酸-半胱氨酸甲酯。
步骤4中所述的碱可以是NaOH、KOH等,优选为NaOH,更优选为2N NaOH。
步骤4中所述的氯化氢-乙酸乙酯溶液的浓度优选为6N氯化氢-乙酸乙酯溶液。
动物抗血栓模型试验证实,本发明通式(I)化合物具有良好的溶血栓活性,可作为抗血栓剂应用。
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
本发明中所出现的术语或缩略语的说明:
THF 四氢呋喃
DCC 二环己基碳二亚胺
DCU 二环己基脲
OBzl 苄氧基
Boc 叔丁氧羰基
HOBt N-羟基苯并三唑
TLC 薄层层析
DMF 二甲基甲酰胺
NMM N-甲基吗啉
具体实施方式
本发明通式(I)化合物(3a-t)的合成路线
I)甲醛和浓盐酸;II)(Boc)2O,1N氢氧化钠,四氢呋喃;III)L-AA-oMe、DCC,HoBt和NMM;IV)2N NaOH水溶液;V)4N氯化氢-乙酸乙酯溶液;
在1a和2a中AA=Ala、1b和2b中AA=Gly、1c和2c中AA=Val、1d和2d中AA=Phe、1e和2e中AA=Leu、1f和2f中AA=Ileu、1g和2g中AA=Trp、1h和2h中AA=Ser、1i和2i中AA=Thr、1j和2j中AA=Pro、1k和2k中AA=Met、1l和2l中AA=Asn、1m和2m中AA=Gln、1n和2n中AA=His、1o和2o中AA=Lys、1p和2p中AA=Lys(Z)-OBzl、1q和2q中AA=Asp(OMe)、1r和2r中AA=Glu(OMe)、1s和2s中AA=Arg、1t和2t中AA=Cys。在3a中AA=Ala、3b中AA=Gly、3c中AA=Val、3d中AA=Phe、3e中AA=Leu、3f中AA=Ileu、3g中AA=Trp、3h中AA=Ser、3i中AA=Thr、3j中AA=Pro、3k中AA=Met、3l中AA=Asn、3m中AA=Gln、3n中AA=His、3o中AA=Lys、3p中AA=Lys、3q中AA=Asp、3r中AA=Glu、3s中AA=Arg、3t中AA=Cys-Cys。
实施例1制备(3S)-1,2,3,4-四氢异喹啉-3-羧酸
往4.0g(24.2mmol)L-苯丙氨酸中先逐滴加入21.6ml甲醛,再逐滴加入36ml35%浓盐酸。得到的混悬液油浴加热至80-90C搅拌2两个小时苯丙氨酸完全溶解,反应2.5小时后,开始有白色沉淀生成,反应7小时,TLC(CHCl3/CH3OH=5/1)显示L-苯丙氨酸消失,抽滤得4.2g无色固体,将所得无色固体加入到86ml乙醇(80%)中80℃油浴加热9小时,至无色固体溶解,冷却至室温,慢慢滴加1ml(1.376g氢氧化钾溶于1ml蒸馏水)氢氧化钾溶液,有无色沉淀析出,过滤得4.02g(94%)标题化合物,为无色固体。Mp.302-303C;ESI-MS(m/e)178[M+H]+;[α]D 25 20=-68(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.9(s,1H),7.0(m,4H),3.80(m,3H),3.03(d.1H),2.78(d,1H),2.0(s,1H);1HNMR(CDCl3-d)δ/ppm=12.9(s,1H),8.91(m,1H),7.56(d,J=7.5Hz,1H),7.44(d,J=8.0Hz,1H),7.23(t,J=7.7Hz,1H),7.22(t,J=8.2Hz,1H),4.332(m,3H),2.816(m,2H,);13C-NMR(CDCl3-d)δ/ppm=30.2,46.4,56.6,35.5,125.6,126.8,128.4,127.2,135.9,173.2。
实施例2制备(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸
冰浴下把2.49g(62.15mmol)氢氧化钠溶入62.2ml水,然后加入10g(56.49mmol)(3S)-1,2,3,4-四氢异喹啉-3-羧酸制成混悬液。用40ml四氢呋喃溶解14.8g(67.8mmol)(Boc)2O,加入混悬液中。反应混合物搅拌48小时,溶液变澄清,TLC(乙酸乙酯/石油醚:1∶3)示(3S)-1,2,3,4-四氢异喹啉-3-羧酸消失,停反应。反应混合物减压浓缩除去四氢呋喃,得到的油状物用乙酸乙酯溶解。得到的溶液依次用5%KHSO4和饱和NaCl水溶液洗。有机层用无水硫酸钠干燥、过滤、滤液减压浓缩至干,得到的油状物用乙酸乙酯/石油醚(1∶10)搅拌24小时,得到的无色固体过滤,得到12.5g(79.9%)标题化合物。ESI-MS(m/e)278[M+H]+,[α]D 25 20=-0.12(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.2(s,1H),7.563(d,J=7.5Hz,1H),7.44(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.220(t,J=7.7Hz,1H),4.332(m,3H),3.12(m,2H),2.816(m,2H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=176.8,169.8,137.5,132.8,129.0,127.8,126.9,125.2,82.9,60.7,56.9,51.3,,28.2,25.5。
实施例3制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸甲酯(1a)
冰浴下往0.256g(0.924mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸与2ml无水THF的溶液中加0.151g(1.109mmol)N-羟基苯并三氮唑(HOBt),搅拌10分钟后加入0.228g(0.108mmol)二环己基碳二亚胺(DCC),得到反应液(I)。把0.143g(0.102mmol)HCl·AlaOMe悬浮于4ml无水THF中,加1mlN-甲基吗啉(NMM)调pH值8~9,搅拌35分钟得到反应液(II)。把(I)加入(II)中,室温搅拌12h,TLC(乙酸乙酯/石油醚,1∶3)显示(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸消失。滤出二环己基脲(DCU),滤液减压浓缩至干,残留物用15ml乙酸乙酯溶解。得到的溶液依次用饱和NaHCO3水溶液洗、饱和NaCl水溶液洗,5%KHSO4水溶液洗,饱和NaCl水溶液洗,饱和NaHCO3水溶液洗,饱和NaC水溶液l洗至中性。乙酸乙酯层用无水Na2SO4干燥、过滤、滤液减压浓缩得0.3g(89.8%)标题化合物,为无色固体。ESI-MS(m/e)363[M+H]+,[α]D 25=-0.17(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.34(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.12(t,J=8.2Hz,7.2,1H),4.442(t,1H),4.182(m,6H),3.120(m,2H)2.821(m,2H),1.420(m,9H),1.378(d,J=6.6Hz,3H);13C-NMR(CDCl3-d)δ/ppm=172.8,168.9,137.2,132.4,129.0,127.5,127.1,124.9,83.2,69.5,57.2,53.1,52.0,49.8,29.2,25.6,16.6。
实施例4制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-甘氨酸甲酯(1b)
按照实施例3的操作,从0.108g(0.39mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.045g(0.51mmol)HCl·Gly-OMe制得得0.116g(85.3%)标题化合物,为无色固体。ESI-MS(m/e)349[M+H]+,[α]D 25=-15.84(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.299(m,6H),3.120(m,2H),2.821(m,2H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.1,169.1,168.9,138.2,132.3,128.6,127.6,127.1,124.9,82.0,68.1,57.2,54.8,51.9,41.2,29.3,26.2。
实施例5制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-缬氨酸甲酯(1c)
按照实施例3的操作,从0.203g(0.73mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.144g(0.86mmol)HCl·Val-OMe制得0.28g(98%)标题化合物,为油状物。ESI-MS(m/e)391[M+H]+,[α]D 25=-0.2169(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.85Hz,1H),4.282(t,1H),4.315(m,6H),3.12(m,2H),2.821(m,2H),2.156(dd,J=6.6Hz,J=5.7Hz,2H),1.42(m,9H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=17.6,171.8,171.2,169.6,137.2,133.6,128.9,127.8,127.5,125.6,82.0,68.9,56.8,56.0,53.4,52.0,30.1,29.3,27.6,17.3。
实施例6制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苯丙氨酸甲酯(1d)
按照实施例3的操作,从2.0g(7.22mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和1.68g(9.39mmol)HCl·Phe-OMe制得3.0g(95%)标题化合物,为透明油状物。ESI-MS(m/e)439[M+H]+,[α]D 25=-0.2169(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=9.061(d,J=8.4Hz,1H),7.012-7.450(m,9H),4.299(m,6H),4.252(t,1H),3.020(m,2H),2.880(m,2H),1.450(m,9H),1.345(m,2H);13C-NMR(CDCl3-d)δ/ppm=169.6,133.3,128.2,128.1,127.9,127.5,127.3,126.2,125.7,80.2,69.5,53.9,53.5,52.0,37.5,29.3,27.5。
实施例7制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-亮氨酸甲酯(1e)
按照实施例3的操作,从0.237g(0.856mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.184g(0.102mmol)HCl·Leu-OMe制得0.38g(91.0%)标题化合物,为油状物。ESI-MS(m/e)405[M+H]+,[α]D 25=-14.1080(c=1.0,甲);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.120(m,2H),2.821(m,2H),1.700(m,2H),1.42(m,9H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=171.6,170.2,168.2,137.2,133.9,128.6,127.8,127.3,125.9,80.2,68.9,55.9,53.4,51.8,49.5,41.0,29.5,27.9,22.9,22.2。
实施例8制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-异亮氨酸甲酯(1f)
按照实施例3的操作,从0.256g(0.924mmo1)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.218g(1.20mmol)HCl·Ile-OMe制得0.37g(97%)标题化合物,为油状物。ESI-MS(m/e)405[M+H]+,[α]D 25=-11.11(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.292(t,1H),4.282(m,6H),3.12(m,2H),2.821(m,3H),1.42(m,9H),1.28(dd,J=6.6Hz,J=5.7Hz,2H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.8,169.9,137.2,133.4,128.9,127.9,127.3,125.6,81.2,68.9,157.0,53.4,53.2,51.8,36.4,30.0,27.2,26.2,15.8,11.5。
实施例9制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-色氨酸甲酯(1g)
按照实施例3的操作,从0.3g(1.083mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.354g(1.45mmol)HCl·Trp-OMe制得0.45g(87.2%)标题化合物,为油状物。ESI-MS(m/e)478[M+H]+,[α]D 25=-7.99(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=10.965(s,1H),9.061(d,J=8.4Hz,1H),6.986-7.499(m,9H),4.282(t,1H),2.821(m,2H),4.280(m,6H),3.12(m,2H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.9,171.9,168.9,137.6,136.8,128.4,127.9,127.3,125.8,122.9,122.6,122.1,119.8,112.0,110.9,81.2,68.9,57.2,54.3,51.8,30.9,29.4,27.6。
实施例10制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丝氨酸甲酯(1h)
按照实施例3的操作,从0.554g(2.0mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.333g(2.14mmol)HCl·Ser-OMe制得0.72g(95%)标题化合物,为油状物。ESI-MS(m/e)379[M+H]+,[α]D 25=-7.45(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7..5Hz,1H),7.120(t,J=7.7Hz,1H),5.25(s,1H),4.282(t,1H),4.280(m,6H),3.12(m,2H),2.821(m,3H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.9,169.7,137.8,134.2,128.9,127.5,127.3,125.9,81.3,61.9,61.2,57.1,54.9,54.4,51.8,29.5,27.9。
实施例11制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苏氨酸甲酯(1i)
按照实施例3的操作,从0.24g(0.866mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.191g(1.126mmol)HCl·Thr-OMe制得0.32g(94%)标题化合物,为油状物。ESI-MS(m/e)393[M+H]+,[α]D 25=-42.43(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.34(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.120(m,2H),2.821(m,3H),2.152(s,1H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.6,167.9,137.1,129.1,127.9,127.2,125.6,83.1,68.2,67.9,58.2,53.7,51.2,51.1,28.2,27.8,18.6。
实施例12制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-酪氨酸甲酯(1j)
按照实施例3的操作,从0.24g(0.866mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.725g(3.72mmol)HC l·lTyr-OMe制得0.58g(87.4%)标题化合物,为油状物。ESI-MS(m/e)455[M+H]+,[α]D 25=-23.26(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),7.072(m,J=8.0Hz,4H),6.702(d,J=8.4Hz,2H),4.282(t,1H),4.280(m,6H),3.120(m,2H),2.821(m,3H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,167.1,156.8,133.1,132.4,129.9,129.6,128.1,127.8,127.3,125.1,116.1,115.7,83.2,69.1,57.2,53.8,53.1,52.0,37.8,37.2,29.7,27.2。
实施例13制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-脯氨酸甲酯(1k)
按照实施例3的操作,从0.229g(0.827mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.148g(0.9mmol)HCl·Pro-OMe制得0.31g(95.3%)标题化合物,为无色固体。ESI-MS(m/e)388[M+H]+,[α]D 25=-18.78(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.763(d,J=6.3Hz,1H),3.682(s,1H),3.120(m,2H),2.821(m,3H),1.973(d,J=8.7Hz,4H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.8,172.1,169.7,137.1,133.3,127.9,127.5,127.2,125.9,82.1,65.6,58.6,56.8,53.8,52.1,47.1,29.9,28.8,22.6。
实施例14制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-蛋氨酸甲酯(1l)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.229g(1.405mmol)HCl·Met-OMe制得0.22g(49.8%)标题化合物,为无色固体。ESI-MS(m/e)409[M+H]+,[α]D 25=-12.90(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.120(m,2H),2.821(m,2H),2.293(m,?H),1.42(m,9H),1.280(m,2H);13C-NMR(CDCl3-d)δ/ppm=171.6,171.8,169.2,137.6,127.2,127.6,125.8,128.9,81.3,69.1,56.7,53.2,52.9,52.3,31.2,27.9,17.8,29.1。
实施例15制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬酰胺甲酯(1m)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.255g(1.397mmol)HCl·Asn-OMe制得0.43g(95%)标题化合物,为油状物。ESI-MS (m/e)406[M+H]+,[α]D 25=-6.4978(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),6.2(S,1H),4.282(t,1H),4.280(m,6H),3.12(m,2H),2.821(m,4H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=174.5,171.8,168.9,137.2,133.7,128.6,127.5,127.3,125.9,82.9,69.0,53.3,52.0,37.2,17.8。
实施例16制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷氨酰胺甲酯(1n)按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.267g(1.397mmol)HCl·Gln-OMe制得0.42g(98%)标题化合物,为油状物。ESI-MS(m/e)421[M+H]+,[α]D 25=-8.50(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),8.1(m,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.120(m,2H),2.821(m,6H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.9,171.9,171.6,168.9,137.1,133.5,128.9,125.8,127.5,127.2,82.3,68.2,56.1,53.4,51.3,51.2,34.2,28.9,27.2,26.8。
实施例17制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-组氨酸甲酯(1o)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.287g(1.397mmol)HCl·His-OMe制得0.41g(95%)标题化合物,为油状物。ESI-MS(m/e)329[M+H]+,[α]D 25=-6.67(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=9.116(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.145(m,2H),3.12(m,2H),2.821(m,2H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=1171.9,171.6,168.9,137.1,133.8,133.1,128.9,127.5,127.2,125.8,118.7,81.3,68.2,56.1,53.4,52.2,51.3,35.6,30.0,28.9,27.2。
实施例18制备N,N’-二-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸甲酯(1p’)
按照实施例3的操作,从0.3g(1.093mmo1)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和1.073g(1.465mmol)HCl·Lys-OMe制得0.306g(41.3%)标题化合物,为油状物。ESI-MS(m/e)679[M+H]+,[α]D 25=-6.55(c=1.0,甲醇)。
实施例19制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-(侧链Z保护)赖氨酸苄酯(1p)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.518g(1.397mmol)HCl·Lys(Z)-OBzl制得0.596g(95%)标题化合物,为油状物。ESI-MS(m/e)631[M+H]+,[α]D 25=-19.90(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),6.986-7.599(m,14H),5.340(d,J=6.3Hz,2H),4.282(t,1H),4.182(m,9H),3.12(m,2H),2.821(m,2H),2.21(m,5H),1.355(m,13H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,169.6,142.8,137.6,136.5,133.7,125.2~128.9,82.7,68.8,67.8,56.8,54.8,53.7,52.8,49.5,32.0,30.2,28.7,27.9,21.7。
实施例20制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬氨酸二甲酯(1q)
按照实施例3的操作,从0.3g(1.093mmo1)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.256g(1.397mmol)HCl·Asp-(OMe)2制得0.39g(95%)标题化合物,为油状物。ESI-MS(m/e)407[M+H]+,[α]D 25=-3.24(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.681(m,6H),3.120(m,2H),2.821(m,2H),2.756(m,3H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.1,172.8,171.6,169.6,137.9,133.6,127.6,127.0,126.9,124.1,81.8,69.5,56.7,53.8,51.7,48.2,37.9,29.1,27.6。
实施例21制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷氨酸二甲酯(1r)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.275g(1.397mmol)HCl·Glu-(OMe)2制得0.415g(98%)标题化合物,为油状物。ESI-MS(m/e)420[M+H]+,[α]D 25=-3.24(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.681(m,6H),3.120(m,2H),2.821(m,2H),1.886(m,4H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.2,172.8,171.6,169.6,137.9,133.6,127.6,127.0,126.9,124.1,81.8,69.5,56.7,53.8,51.6,50.7,29.1,27.8,27.6,26.6。
实施例22制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-精氨酸甲酯(1s)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.314g(1.397mmol)HCl·Arg-OMe制得0.25g(51%)标题化合物,为油状物。ESI-MS(m/e)448[M+H]+,[α]D 25=-1.57(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=9.550(m,3H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.681(m,6H),3.120(m,2H),2.821(m,4H),2.083(m,1H),1.884(m,1H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,169.6,149.7,137.2,133.6,128.9,127.9,127.2,125.6,83.2,68.5,53.7,57.2,52.7,51.0,37.2,29.1,28.7,26.7,24.5。
实施例23制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-半胱甲酯(1t)
按照实施例3的操作,从0.3g(1.093mmol)(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸和0.213g(0.124mmol)HCl·Cys-OMe制得0.390g(98)标题化合物,为油状物。ESI-MS(m/e)395[M+H]+,[α]D 25=-31.44(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,6H),3.120(m,2H),2.821(m,3H),2.083(m,1H),1.884(m,1H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.6,171.2,169.7,156.8,137.2,133.6,128.6,127.6,127.1,125.1,81.9,68.7,26.7,55.2,53.2,51.6,29.3,27.2。
实施例24制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸(2a)
将560mg(1.544mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸甲酯溶于4ml甲醇,冰浴下向得到的溶液中滴入5ml NaOH(2N)水溶液。,溶液渐变为黄色,5小时后TLC(乙酸乙酯/石油醚,1∶3)显示N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸甲酯消失,减压浓缩蒸去溶剂,残留物加入30ml饱和KHSO4调PH值为1-2,用乙酸乙酯萃取3次,合并的乙酸乙酯层用饱和NaCl洗1次,用无水Na2SO4干燥。过滤,滤液减压浓缩,得0.516g(96%)标题化合物,为无色固体。ESI-MS(m/e)348[M-H]-,[α]D 25=-0.17(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.282(m,3H),3.120(m,2H),2.821(m,2H),1.42(m,9H),1.378(d,J=6.6Hz,3H);13C-NMR(CDCl3-d)δ/ppm=172.8,168.9,137.2,132.4,129.0,127.5,127.1,124.9,83.2,69.5,57.2,53.1,50.8,25.6,16.7。
实施例25制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-甘氨酸(2b)
按照实施例24的操作,从520mg(1.49mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-甘氨酸甲酯制得0.480g(96%)标题化合物,为无色固体。ESI-MS(m/e)333[M-H]-,[α]D 25=-0.13(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.299(m,3H),4.282(t,1H),3.12(m,2H),2.821(m,2H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.1,169.1,168.9,138.2,132.3,128.6,127.7,127.1,124.7,82.0,69.1,57.2,54.8,42.2,28.3,26.2。
实施例26制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-缬氨酸(2c)
按照实施例24的操作,从0.380mg(0.974mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-缬氨酸甲酯制得0.381g(95%)标题化合物,为油状物。ESI-MS(m/e)407[M-H]-,[α]D 25=-6.73(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.621(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.228(t,J=7.5Hz,1H),7.24(d,J=8.0Hz,1H),7.120(t,J=7.7Hz,1H),4.299(m,3H),4.282(t,1H),3.22(m,2H),2.821(m,2H),2.156(dd,J=6.5Hz,J=5.7Hz,2H),1.420(m,9H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=171.8,171.2,169.6,137.2,133.6,128.9,127.8,127.5,125.6,82.0,68.9,56.8,56.0,53.4,30.1,29.3,27.6,17.8,17.2。
实施例27制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苯丙氨酸(2d)
按照实施例24的操作,从0.595g(1.36mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苯丙氨酸甲酯制得0.553g(96%)标题化合物,为无色固体。ESI-MS(m/e)423[M-H]-,[α]D 25=-5.52(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.500(s,1H),9.061(d,J=8.4Hz,1H),7.231(m,9H),4.299(m,3H),4.252(t,1H),3.020(m,2H),2.871(m,2H),1.45(m,9H),1.345(m,2H);13C-NMR(CDCl3-d)δ/ppm=169.7,133.4,128.1,127.8,128.2,127.9,127.5,127.3,126.2,125.7,80.2,69.5,53.9,53.5,37.5,29.3,27.5。
实施例28制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-亮氨酸(2e)
按照实施例24的操作,从1.20g(2.97mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-亮氨酸甲酯制得1.095g(95%)标题化合物,为油状物。ESI-MS(m/e)389[M-H]-,[α]D 25=-0.17(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),8.701(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.821(m,2H),1.957(m,2H),1.418(m,9H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=172.3,170.2,168.2,137.2,134.9,128.6,127.8,127.3,125.9,81.2,68.9,55.9,53.4,49.5,41.0,29.5,27.6,22.4,21.9。
实施例29制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-异亮氨酸(2f)
按照实施例24的操作,从0.6g(1.485mmol)制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-异亮氨酸甲酯制得0.544g(94%)标题化合物,为无色固体。ESI-MS(m/e)389[M-H]-,[α]D 25=-1.13(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.292(t,1H),4.280(m,3H),3.120(m,2H),2.821(m,3H),1.420(m,9H),1.280(dd,J=6.6Hz,J=5.7Hz,2H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=172.8,170.8,169.7,137.2,133.4,128.9,127.9,127.3,125.6,82.2,68.9,57.0,53.4,53.2,36.4,30.0,27.2,16.8,12.3。
实施例30制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-色氨酸(2g)
按照实施例24的操作,从0.597g(1.231mmol)制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-色氨酸甲酯制得0.513g(90%)标题化合物,为淡黄色固体。ESI-MS(m/e)462[M-H]-,[α]D 25=-7.62(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),10.965(s,1H),9.061(d,J=8.4Hz,1H),7.243(m,9H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.821(m,2H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.9,171.9,169.9,168.9,137.6,136.8,128.9,128.4,127.9,127.3,125.8,122.9,122.6,122.1,119.7,112.8,111.9,81.3,69.9,57.2,54.3,30.6,29.5,26.6。
实施例31制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丝氨酸(2h)
按照实施例24的操作,从0.4g(1.06mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丝氨酸甲酯制得0.38g(99%)标题化合物,为油状物。ESI-MS(m/e)363[M-H]-,[α]D 25=-3.30(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.218(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),5.250(s,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.821(m,3H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.6,169.8,137.8,134.2,128.9,127.5,127.3,125.9,81.3,61.9,61.2,57.1,54.9,54.4,29.6,28.9。
实施例32制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苏氨酸(2i)
按照实施例24的操作,从0.8g(2.04mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苏氨酸甲酯制得0.756g(98%)标题化合物,为无色固体。ESI-MS(m/e)377[M-H]-,[α]D 25=-22.43(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.820(m,3H),2.152(s,1H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.6,167.8,137.2,129.1,127.9,127.2,125.6,83.1,68.9,68.2,58.2,53.7,52.2,28.5,27.8,9.6。
实施例33制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-酪氨酸(2j)
按照实施例24的操作,从0.183g0.403mmol)制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-酪氨酸甲酯制得0.16g(90%)标题化合物,为无色固体。ESI-MS(m/e)439[M-H]-,[α]D 25=-11.52(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),7.077(m,J=8.1Hz,4H),6.702(d,J=8.4Hz,2H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.820(m,3H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,167.2,156.8,132.4,133.1,129.9,129.6,128.1,127.8,127.3,125.1,117.1,115.7,83.2,69.1,57.2,53.8,53.1,37.8,37.2,29.7,22.2。
实施例34制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-脯氨酸(2k)
按照实施例24的操作,从0.776g(2mmol)制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-脯氨酸甲酯制得0.696g(93%)标题化合物,为无色固体。ESI-MS(m/e)373[M-H]-,[α]D 25=-6.06(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.763(d,J=6.3Hz,1H),3.682(s,1H),3.12(m,2H),2.820(m,3H),1.973(d,J=8.7Hz,4H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.8,172.2,169.7,137.1,133.3,127.9,127.5,127.2,125.9,82.3,66.6,58.6,56.8,53.8,52.1,29.9,28.9,22.7。
实施例35制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-蛋氨酸(2l)
按照实施例24的操作,从0.86g(2.04mmol)制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-蛋氨酸甲酯制得0.79g(95%)标题化合物,为无色固体。ESI-MS(m/e)407[M-H]-,[α]D 25=-9.63(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.12(m,2H),2.820(m,2H),2.293(m,?H),1.42(m,9H),1.280(m,2H);13C-NMR(CDCl3-d)δ/ppm=172.6,171.8,169.4,137.6,128.9,127.6,127.3,125.8,81.5,69.1,56.7,53.2,52.9,31.2,29.2,27.9,18.8。
实施例36制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬酰胺(2m)
按照实施例24的操作,从0.427g(1.054mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬酰胺甲酯制得0.371g(90%)标题化合物,为无色固体。ESI-MS(m/e)418[M-H]-,[α]D 25=-9.42(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),6.200(s,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.820(m,4H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.5,171.8,168.9,137.2,134.7,128.6,127.5,127.1,125.9,82.9,69.0,53.3,37.3,17.9。
实施例37制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷胺酰胺(2n)
按照实施例24的操作,从0.0.89g(2.13mmol)制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷胺酰胺甲酯制得0.874g(98%)标题化合物,为无色固体。ESI-MS(m/e)421[M-H]-,[α]D 25=-6.23(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,J=8.4Hz,1H),8.100(m,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.820(m,6H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.8,172.9,171.6,167.9,137.1,133.5,128.9,127.5,127.2,125.8,81.3,68.2,56.2,53.4,51.3,34.1,28.9,27.3,26.8。
实施例38制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-组氨酸(2o)
按照实施例24的操作,从1.048g(2.45mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-组氨酸甲酯制得0.76g(75%)标题化合物,为油状物。ESI-MS(m/e)413[M-H]-,[α]D 25=-1.72(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),9.116(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.145(m,2H),3.120(m,2H),2.820(m,2H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,168.9,137.1,135.6,135.6,133.8,133.1,128.9,127.5,127.2,125.8,118.7,81.3,68.2,56.1,53.4,52.2,30.0,27.2,28.9。
实施例39制备N,N’-二-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸(2p’)
按照实施例24的操作,从1.03g(1.52mmol)N,N’-二-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸甲酯制得0.979g(97%)标题化合物,为油状物。ESI-MS(m/e)663[M-H]-。
实施例40制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸(2p)
先将1.5g(2.38mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-(侧链Z保护)赖氨酸苄酯溶于5ml无水乙醇,往得到的溶液中加入0.200gPt/C。室温下往该悬浮液,通96hH2,TLC(CHCl3/CH3OH,1∶1)显示N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-(侧链Z保护)赖氨酸苄酯消失。反应混合物过滤,滤液减压浓缩,得到0.92g(96%)标题化合物,为油状物。ESI-MS(m/e)404[M-H]-,[α]D 25=-3.37(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,J=8.4Hz,1H),7.293(m,14H),4.282(t,1H),4.182(m,3H),3.120(m,2H),2.820(m,2H),2.211(m,5H),1.36(m,13H);13C-NMR(CDCl3-d)δ/ppm=172.9,171.6,169.6,142.8,137.6,136.6,134.7,125.2~128.7,82.7,68.8,67.8,56.8,54.8,53.7,52.8,32.0,30.2,28.9,27.9,22.7。
实施例41制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬氨酸(2q)
按照实施例24的操作,从0.368g(0.875mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬氨酸甲酯制得0.340g(99%)标题化合物,为油状物。ESI-MS(m/e)391[M-H]-,[α]D 25=-10.46(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.700(s,1H),11.700(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.820(m,2H),2.756(m,3H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.2,172.8,171.6,169.6,137.8,133.6,127.6,127.1,126.9,124.1,82.8,69.6,56.7,53.8,48.3,37.9,29.4,28.6。
实施例42制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷氨酸(2r)
按照实施例24的操作,从0.4g(0.421mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷氨酸甲酯制得0.348g(89.9%)标题化合物,为无色固体。ESI-MS(m/e)405[M-H]-,[α]D 25=-10.46(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),11.700(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.120(m,2H),2.821(m,2H),1.884(m,1H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=173.1,172.8,171.6,169.6,137.9,127.6,127.0,124.1,123.6,82.8,69.5,56.7,53.8,50.7,29.3,27.8,27.6,26.7。
实施例43制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-精氨酸(2s)
按照实施例24的操作,从0.446g(1.0mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-精氨酸甲酯制得0.4g(93%)标题化合物,为油状物。ESI-MS(m/e)432[M-H]-,[α]D 25=-20.52(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=12.500(s,1H),9.102(m,3H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=75Hz,1H),7.120(t,J=7.7Hz,1H),4.282(t,1H),4.280(m,3H),3.12(m,2H),2.817(m,4H),1.884(m,4H),1.42(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.6,171.9,169.8,159.7,137.2,133.6,128.9,127.9,127.2,125.6,83.2,68.5,57.2,53.7,52.7,37.2,29.7,26.7,25.5。
实施例44制备N,N’-二-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-胱氨酸(2t)
按照实施例24的操作,从0.77g(1.00mmol)N,N’-二-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-胱氨酸甲酯制得0.733g(97%)标题化合物,为油状物。ESI-MS(m/e)757[M-H]-,[α]D 25=-20.12(c=1.0,甲醇);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.282(m,4H),3.120(m,2H),2.820(m,3H),2.082(m,1H),1.884(m,1H),1.420(m,9H);13C-NMR(CDCl3-d)δ/ppm=171.6,171.2,169.7,156.8,137.2,133.6,128.6,127.6,127.1,125.1,81.9,68.7,55.2,53.2,29.4,27.2,26.7。
实施例45制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸(3a)
将0.161g(0.463mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸溶于3ml乙酸乙酯中,再往得到的溶液中加5ml氯化氢-乙酸乙酯(4N)溶液。0℃搅拌6h,TLC(氯仿/甲醇,3/1)显示N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丙氨酸消失。反应混合物减压浓缩至干,残留物用10ml乙酸乙酯溶胶解,再减压浓缩至干。该操作反复三次。残留物加20ml乙醚研磨,滤得0.109g(95%)标题化合物,为无色固体。Mp.121-123℃。ESI-MS(m/e)248[M+H]+,[α]D 25=-164.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.900(s,1H),8.910(m,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.280(m,3H),2.820(m,2H),1.378(d,J=6.6Hz,3H);13C-NMR(CDCl3-d)δ/ppm=168.9,16.7,174.8,50.8,69.5,25.6,137.2,127.5,127.1,124.9,129.0,132.4,57.2,53.1。
实施例46制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-甘氨酸(3b)
按照实施例45的操作,从1.09g(5.57mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-甘氨酸制得750mg(95%)标题化合物,为无色固体。Mp.150-152℃。ESI-MS(m/e)235[M+H]+,[α]D 25=-32.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.900(s,1H),8.910(m,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.280(m,3H),2.820(m,2H),1.378(d,J=6.6Hz,3H);13C-NMR(CDCl3-d)δ/ppm=172.1,169.1,138.2,132.3,128.6,127.7,127.1,124.7,69.1,57.2,54.8,42.2,26.2。
实施例47制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-缬氨酸(3c)
按照实施例45的操作,从1.004g(2.669mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-缬氨酸制得0.7g(95%)标题化合物,为无色固体。Mp.202-204℃。ESI-MS(m/e)277[M+H]+,[α]D 25=-14.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.900(s,1H),8.91(m,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),
7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.282(m,3H),2.820(m,2H),2.156(dd,J=6.5Hz,J=5.7Hz,2H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=171.8,171.2,137.2,133.6,128.9,127.8,127.5,125.6,68.9,56.8,56.0,53.4,30.1,27.6,17.8,17.2。
实施例48制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苯丙氨酸(3d)
按照实施例45的操作,从0.553g(1.304mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苯丙氨酸制得0.392g(92.8%)标题化合物,为淡黄色固体。Mp.106-108℃。ESI-MS(m/e)325[M+H]+,[α]D 25=-42.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.680(s,1H),9.061(d,J=8.4Hz,1H),7.231(m,9H),4.280(m,3H),4.252(t,1H),2.861(m,2H),1.345(m,2H);13C-NMR(CDCl3-d)δ/ppm=174.9,171.8,133.4,128.2,128.1,127.9,127.8,127.5,127.3,126.2,125.7,69.5,53.9,53.5,37.5,27.5。
实施例49制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-亮氨酸(3e)
按照实施例42的操作,从0.598g(1.533mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-亮氨酸制得400mg(90%)标题化合物,为淡黄色固体。Mp.145-147℃。ESI-MS(m/e)291[M+H]+,[α]D 25=-16.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.900(s,1H),8.910(m,1H),8.721(d,J=8.4hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.282(t,1H),4.280(m,3H),2.820(m,2H),1.345(m,2H),0.965(m,6H);13C-NMR(CDCl3-d)δ/ppm=172.3,170.2,137.2,134.9,128.6,127.8,127.3,125.9,68.9,55.9,53.4,49.5,41.0,27.6,22.4,21.9。
实施例50制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-异亮氨酸(3f)
按照实施例45的操作,从0.581g(1.491mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-异亮氨酸制得0.415g(96%)标题化合物,为无色固体。Mp.126-128℃。ESI-MS(m/e)291[M+H]+,[α]D 25=-10.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.900(s,1H),8.910(m,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.280(m,3H),4.282(t,1H),2.820(m,3H),1.28(dd,J=6.5Hz,J=5.7Hz,2H),0.955(m,6H);13C-NMR(CDCl3-d)δ/ppm=172.8,170.8,137.2,133.4,128.9,127.9,127.3,125.6,68.9,57.0,53.4,53.2,36.4,27.2,16.8,12.3。
实施例51制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-色氨酸(3g)
按照实施例45的操作,从0.13g(1.108mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-色氨酸制得0.362g(90%)标题化合物,为紫色固体。Mp.146-147℃。ESI-MS(m/e)364[M+H]+,[α]D 25=-52.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=10.965(s,1H),10.900(s,1H),9.061(d,J=8.4Hz,1H),8.861(m,1H),7.293(m,9H),4.280(m,3H),4.252(t,1H),2.858(m,2H);13C-NMR(CDCl3-d)δ/ppm=172.9,171.9,168.9,137.6,136.8,128.9,128.4,127.9,127.3,125.8,122.9,122.6,122.1,119.7,112.8,111.9,69.9,57.2,54.3,29.5,26.6。
实施例52制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丝氨酸(3h)
按照实施例45的操作,从1.09g2.99mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-丝氨酸制得0.75g(95%)标题化合物,为无色固体。Mp.102-104℃。ESI-MS(m/e)265[M+H]+,[α]D 25=-2.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.900(s,1H),8.861(m,1H),8.821(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.240(d,J=8.0Hz,1H),7.120(t,J=7.7Hz,1H),7.028(t,J=7.5Hz,1H),5.25(s,1H),4.042(t,1H),4.280(m,3H),2.856(m,2H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.6,137.8,134.2,128.9,127.5,127.3,125.9,61.9,61.2,57.1,54.9,54.4,28.9。
实施例53制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苏氨酸(3i)
按照实施例45的操作,从2.08g(5.5mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-苏氨酸制得1.51g(98%)标题化合物,为无色固体。Mp.100-102℃。ESI-MS(m/e)279[M+H]+,[α]D 25=-14.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.900(s,1H),8.861(m,1H),8.951(d,J=8.4Hz,1H),7.463(d,J=7.5Hz,1H),7.384(d,J=8.1Hz,1H),7.120(t,J=7.7Hz,1H),7.028(t,J=7.5Hz,1H),4.334(m,3H),4.282(t,1H),2.8866(m,2H),2.152(s,1H);13C-NMR(CDCl3-d)δ/ppm=172.8,171.6,137.2,129.1,127.9,127.2,125.6,68.9,68.2,58.2,53.7,52.2,27.8,19.6。
实施例54制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-酪氨酸(3j)
按照实施例45的操作,从0.279g(0.634mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-酪氨酸制得0.207g(96%)标题化合物,为无色固体。Mp.120-122℃。ESI-MS(m/e)341[M+H]+,[α]D 25=-72.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.9(s,1H),9.061(d,J=8.4Hz,1H),8.979(d,J=7.5Hz,1H),8.861(m,1H),7.463(d,J=7.6Hz,1H),7.284(d,J=8.1Hz,1H),7.212(t,J=7.7Hz,1H),7.028(t,J=7.0Hz,1H),7.077(m,J=8.1Hz,4H),6.702(d,J=8.4Hz,2H),4.280(m,3H),4.252(t,1H),2.856(m,2H));13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,156.8,132.4,133.1,129.9,129.6,128.1,127.8,127.3,125.1,117.1,115.7,69.1,57.2,53.8,53.1,37.8,37.2,22.2。
实施例55制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-脯氨酸(3k)
按照实施例45的操作,从0.696g(1.86mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-脯氨酸制得0.5g(98%)标题化合物,白色固体,为无色固体。Mp.115-116℃。ESI-MS(m/e)275[M+H]+,[α]D 25=-367.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.900(s,1H),8.861(m,1H),7.463(d,J=7.6Hz,1H),7.284(d,J=8.1Hz,1H),7.212(t,J=7.7Hz,1H),7.028(t,J=7.0Hz,1H),4.280(m,3H),4.252(t,1H),3.763(d,J=6.3Hz,1H),3.682(s,1H),2.856(m,2H),1.973(d,J=8.7Hz,4H);13C-NMR(CDCl3-d)δ/ppm=173.8,172.2,137.1,133.3,127.9,127.5,127.2,125.9,66.6,58.6,56.8,53.8,52.1,28.9,22.7。
实施例56制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-蛋氨酸(3l)
按照实施例45的操作,从0.089g(0.218mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-蛋氨酸制得0061g(91%)标题化合物,为无色固体。Mp.103-105℃。ESI-MS(m/e)275[M+H]+,[α]D 25=-48.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.9(s,1H),9.061(d,J=8.4Hz,1H),8.861(m,1H),7.463(d,J=7.6Hz,1H),7.284(d,J=8.1Hz,1H),7.212(t,J=7.7Hz,1H),7.028(t,J=7.0Hz,1H),4.280(m,3H),4.252(t,1H),2.856(m,2H),2.237(m,2H),1.275(m,2H);13C-NMR(CDCl3-d)δ/ppm=172.6,171.8,137.6,128.9,127.6,127.3,125.8,56.7,53.2,69.1,52.9,31.2,27.9,18.8。
实施例57制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬酰胺(3m)
按照实施例45的操作,从0.374g(0.96mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬酰胺制得0.267g(95.6%)标题化合物,为淡黄色固体。Mp.100-101℃。ESI-MS(m/e)293[M+H]+,[α]D 25=-22.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.900(s,1H),9.061(d,J=8.4Hz,1H),8.861(m,1H),8.721(d,J=8.4Hz,1H),7.463(d,J=7.6Hz,1H),7.284(d,J=8.1Hz,1H),7.212(t,J=7.7Hz,1H),7.028(t,J=7.0Hz,1H),6.200(s,1H),4.252(t,1H),4.282(t,1H),4.280(m,3H),2.856(m,4H);13C-NMR(CDCl3-d)δ/ppm=173.5,171.8,137.2,134.7,128.6,127.5,127.1,125.9,69.0,53.3,37.3,17.9。
实施例58制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷胺酰胺(3n)
按照实施例45的操作,从0.493g(1.23mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷胺酰胺制得0.36g(96%)标题化合物,为无色固体。Mp.87-89℃。ESI-MS(m/e)307[M+H]+,[α]D 25=-62.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.900(s,1H),9.061(d,J=8.4Hz,1H),8.861(m,1H),8.721(d,J=8.4Hz,1H),8.100(m,1H),7.463(d,J=7.6Hz,1H),7.284(d,J=8.1Hz,1H),7.212(t,J=7.7Hz,1H),7.028(t,J=7.0Hz,1H),4.282(t,1H),4.280(m,3H),4.252(t,1H),2.856(m,4H);13C-NMR(CDCl3-d)δ/ppm=173.8,172.9,171.6,137.1,133.5,128.9,127.5,127.2,125.8,68.2,56.2,53.0,51.3,34.1,27.3,26.8。
实施例59制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-组氨酸(3o)
按照实施例45的操作,从0.45g(油状物)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷胺组氨酸制得0.3g(96%)标题化合物,为无色固体。Mp.126-127℃。ESI-MS(m/e)314[M+H]+,[α]D 25=-34.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.820(s,1H),9.116(s,1H),9.05(m,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.133(t,J=7.2Hz,1H),7.036(t,J=7.0Hz,1H),4.442(t,1H),4.280(m,3H),3.145(m,2H),2.856(m,2H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,137.1,135.6,133.8,133.1,128.9,127.5,127.2,125.8,118.7,68.2,56.1,52.2,53.4,30.0,27.2。
实施例60制备N,N’-二-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸(3p’)
按照实施例45的操作,从0.353g(0.532mmo1)N,N’-二-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸制得0.203g(82%)标题化合物,为无色固体。Mp.110-112℃。ESI-MS(m/e)464[M+H]+,[α]D 25=-10.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=10.900(s,1H),9.061(m,2H),8.861(m,2H),7.293(m,8H),4.252(t,1H),4.281(m,6H),2.856(m,4H),2.210(m,4H),1.351(m,4H);13C-NMR(CDCl3-d)δ/ppm=174.9,171.6,171.5,136.2,133.2,128.2,127.8,127.1,125.6,69.1,52.3,47.8,41.6,33.6,29.7,21.2。
实施例61制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸(3p)
按照实施例45的操作,从0.0246g(0.0607mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-赖氨酸制得0.0159g(87%)标题化合物,为无色固体。Mp.107-109℃。ESI-MS(m/e)305[M+H]+,[α]D 25=-28.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=10.9(s,1H),9.061(m,2H),8.861(m,2H),8.721(d,J=8.4Hz,1H),7.294(m,14H),4.252(t,1H),4.280(m,3H),2856(m,2H),2.210(m,4H),1.351(m,4H);13C-NMR(CDCl3-d)δ/ppm=172.9,171.6,142.8,137.6,136.6,134.7,125.2,128.7,68.8,67.8,56.8,54.8,53.7,52.8,32.0,30.2,27.9,22.7。
实施例62制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬氨酸(3q)
按照实施例45的操作,从0.35g(0.894mmol)N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]-L-天冬氨酸制得0.248g(95%)标题化合物,为无色固体。Mp.109-110℃。ESI-MS(m/e)293[M+H]+,[α]D 25=-34.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.400(s,1H),11.700(s,1H),9.05(m,1H),8.91(m,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.281(m,3H),2.856(m,2H),2.755(m,3H);13C-NMR(CDCl3-d)δ/ppm=173.2,172.8,171.6,137.8,133.6,127.6,127.1,126.9,124.1,69.6,56.7,53.8,48.3,37.9,28.6。
实施例63制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷氨酸(3r)
按照实施例45的操作,从0.35g(0.894mmol)N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-谷氨酸制得0.224g(96%)标题化合物,为无色固体。Mp.104-106℃。ESI-MS(m/e)307[M+H]+,[α]D 25=-64.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=12.5(s,1H),11.7(s,1H),8.91(m,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.120(t,J=7.7Hz,1H),4.442(t,1H),4.280(m,3H),2.865(m,2H),2.073(m,1H),1.874(m,1H);13C-NMR(CDCl3-d)δ/ppm=173.1,172.8,171.6,137.9,127.6,127.0,124.1,123.6,69.5,56.7,53.8,50.7,27.8,27.6,26.7。
实施例64制备N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-精氨酸(3s)
按照实施例45的操作,从0.395g(0.91mmol)N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-精氨酸制得0.290g(81%)标题化合物,为无色固体。Mp.203-205℃。ESI-MS(m/e)334[M+H]+,[α]D 25=-26.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),9.100(m,3H),8.910(m,1H),8.721(d,J=8.4Hz,1H),7.553(d,J=7.5Hz,1H),7.340(d,J=8.0Hz,1H),7.228(t,J=7.5Hz,1H),7.12(t,J=7.7Hz,1H),4.442(t,1H),4.280(m,3H),2.856(m,4H),1.874(m,4H);13C-NMR(CDCl3-d)δ/ppm=171.9,171.6,137.2,133.6,128.9,127.9,127.2,125.6,68.5,57.2,53.7,52.7,37.2,26.7,25.5。
实施例65制备N,N’-二-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-胱氨酸(3t)
按照实施例45的操作,从0.565g(1.49mmol)N-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-半胱氨酸制得0.387g(93%)标题化合物,为无色固体。Mp.196-198℃。ESI-MS(m/e)334[M+H]+,[α]D 25=-4.00(c=1.0,水);1HNMR(CDCl3-d)δ/ppm=11.700(s,1H),9.861(m,1H),8.921(d,J=8.4Hz,1H),7.543(d,J=7.5Hz,1H),7.340(d,J=8.2Hz,1H),7.28(t,J=7.6Hz,1H),7.120(t,J=7.7Hz,1H),4.342(t,1H),4.280(m,3H),2.856(m,2H),2.073(m,1H),1.884(m,1H);13C-NMR(CDCl3-d)δ/ppm=171.6,171.2,137.1,133.6,128.6,127.6,127.1,125.1,68.7,56.8,55.2,53.2,26.7,27.2。
试验例1本发明通式(I)化合物(3a-t)的抗血栓活性试验
测定前将3a-t溶于生理盐水。雄性Wistra大鼠(220-240g)用戊巴比妥钠(5.0mg/ml,3ml/kg)麻醉后分离右颈动脉和左颈静脉。把一根6cm长的事先精密称重的丝线放在聚乙烯管中,将插管充满肝素钠的生理盐水溶液(50IU/ml)后,一端插入左侧静脉,从一端加入定量肝素钠抗凝,并加入3a-t的生理盐水溶液(浓度为0.67mg/ml,剂量为5μmol/kg),然后插入右侧动脉。血流从右侧动脉流经聚乙烯管流入左侧静脉,15分钟后取出附有血栓的丝线并记录湿重,附有血栓的丝线在干燥器中放置两周后,称量干重。以生理盐水(NS,3ml/kg)作空白对照,以阿司匹林(剂量1组为0.2mol/kg,剂量2组为500μmol/kg)作阳性对照。结果见表1。
表1的数据表明在5μmol/kg剂量下3a-t具有明显的抗血栓活性。从表1的数据还可以看出,虽然3a-t在相当于1/40000阿司匹林剂量下抗血栓活性弱于阿司匹林,但是在相当于1/100阿司匹林剂量下3a-t的抗血栓活性非常显著地强于阿司匹林。在剂量仅是3a-t100倍的情形下,阿司匹林不显示抗血栓作用。该结果说明,3a-t是优秀的抗血栓剂。
表13a-t治疗对大鼠血栓形成的影响
化合物 | 血栓湿重(X±SDmg) | 血栓干重(X±SD mg) |
NS(3ml/kg) | 28.54±2.62 | 5.87±0.34 |
Aspirin<sup>1</sup> | 13.22±1.67<sup>a</sup> | 2.44±0.71<sup>b</sup> |
Aspirin<sup>2</sup> | 27.60±1.89 | 5.09±0.98 |
IQ | 21.02±1.49<sup>a</sup> | 3.88±0.54<sup>b</sup> |
3a | 21.40±1.29<sup>a</sup> | 3.95±1.07<sup>b</sup> |
3b | 20.64±1.37<sup>a</sup> | 3.81±1.22<sup>b</sup> |
3c | 19.20±1.97<sup>a</sup> | 3.57±0.85<sup>b</sup> |
3d | 19.11±1.68<sup>a</sup> | 3.53±0.67<sup>b</sup> |
3e | 20.43±1.49<sup>a</sup> | 3.77±0.99<sup>b</sup> |
3f | 20.03±1.79<sup>a</sup> | 3.70±0.85<sup>b</sup> |
3g | 21.30±1.06<sup>a</sup> | 3.93±0.97<sup>b</sup> |
3h | 23.58±1.93<sup>a</sup> | 4.25±0.79<sup>c</sup> |
3i | 21.25±1.93<sup>a</sup> | 3.92±0.91<sup>b</sup> |
3j | 19.31±1.48<sup>a</sup> | 3.56±0.68<sup>b</sup> |
3k | 20.35±1.70<sup>a</sup> | 3.75±1.17<sup>b</sup> |
3l | 21.74±1.50<sup>a</sup> | 4.01±0.69<sup>b</sup> |
3m | 20.34±1.90<sup>a</sup> | 3.75±0.58<sup>b</sup> |
3n | 22.08±1.54<sup>a</sup> | 4.07±1.00<sup>b</sup> |
3o | 20.86±1.94<sup>a</sup> | 3.85±0.64<sup>b</sup> |
3p’ | 21.28±1.17<sup>a</sup> | 3.93±0.78<sup>b</sup> |
3p | 21.67±1.71<sup>a</sup> | 4.00±0.79<sup>b</sup> |
3q | 19.69±1.65<sup>a</sup> | 3.63±0.78<sup>b</sup> |
3r | 18.73±1.56<sup>a</sup> | 3.46±0.53<sup>b</sup> |
3s | 20.91±1.77<sup>a</sup> | 3.86±0.90<sup>b</sup> |
3t | 19.25±1.54<sup>a</sup> | 3.55±0.68<sup>b</sup> |
[0172]n=12,a)与NS及Aspirin2组血栓湿重比,p<0.001;b)与NS及Aspirin2组血栓干重比,p<0.001;c)与NS组血栓干重比p<0.001,与Aspirin2组血栓干重比p<0.05.
Claims (6)
3.一种制备权利要求1所述通式(I)化合物的方法,包括:
(1)在浓盐酸存在下将苯丙氨酸与甲醛进行Pictet-Spengler缩合制备(3S)-1,2,3,4-四氢异喹啉-3-羧酸;
(2)在(Boc)2O存在下将(3S)-1,2,3,4-四氢异喹啉-3-羧酸转化为(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸;
(3)在二环己基碳二亚胺和N-甲基吗啉存在下将(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-羧酸与L-氨基酸甲酯偶联制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸甲酯;所述的L-氨基酸甲酯选自丙氨酸甲酯、甘氨酸甲酯、缬氨酸甲酯、苯丙氨酸甲酯、亮氨酸甲酯、异亮氨酸甲酯、色氨酸甲酯、丝氨酸甲酯、苏氨酸甲酯、脯氨酸甲酯、甲硫氨酸甲酯、天冬酰胺甲酯、谷氨酰胺甲酯、组氨酸甲酯、赖氨酸甲酯、天冬氨酸甲酯、谷氨酸甲酯、精氨酸甲酯或酪氨酸甲酯;
(4)在碱溶液中将N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸甲酯水解制备N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸;
(5).在氯化氢-乙酸乙酯溶液中将N-[(3S)-N-Boc-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸脱Boc,即得。
4.按照权利要求3的方法,其特征在于:步骤(4)中所述的碱溶液是NaOH溶液。
5.按照权利要求3的方法,其特征在于:步骤(5)中所述的氯化氢-乙酸乙酯溶液为6N的氯化氢-乙酸乙酯溶液。
6.权利要求1所述通式(I)化合物或N,N’-二-[(3S)-1,2,3,4-四氢异喹啉-3-甲酰基]-L-胱氨酸在制备抗血栓药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610144236A CN101190895B (zh) | 2006-11-30 | 2006-11-30 | N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610144236A CN101190895B (zh) | 2006-11-30 | 2006-11-30 | N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101190895A CN101190895A (zh) | 2008-06-04 |
CN101190895B true CN101190895B (zh) | 2010-05-26 |
Family
ID=39486112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610144236A Expired - Fee Related CN101190895B (zh) | 2006-11-30 | 2006-11-30 | N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101190895B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101899084B (zh) * | 2009-05-26 | 2012-09-05 | 首都医科大学 | (3s)-1,2,3,4-四氢异喹啉-3-羧酸三肽缀合物及其制备方法和应用 |
CN102120727B (zh) * | 2010-01-07 | 2013-08-28 | 首都医科大学 | N-[(3s)-n-氨基酰-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用 |
CN102234277B (zh) * | 2010-05-07 | 2012-12-26 | 首都医科大学 | 氨基酸修饰的1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸及其合成方法和应用 |
CN102477066B (zh) * | 2010-11-30 | 2013-12-04 | 首都医科大学 | N-(s-1,2,3,4-四氢-6,7-二羟基异喹啉-3-甲酰)氨基酸及其合成方法和应用 |
CN102827245A (zh) * | 2011-06-13 | 2012-12-19 | 首都医科大学 | N-[2-(3-乙酰基-2-氧代-2h-吡啶-1-基)-乙酰]-l-氨基酸,其合成方法及应用 |
CN103450343B (zh) * | 2012-06-01 | 2015-08-05 | 首都医科大学 | 四氢异喹啉-3-羧酸修饰的targd七肽、其合成、抗血栓活性和应用 |
CN103450342B (zh) * | 2012-06-01 | 2015-08-05 | 首都医科大学 | 四氢异喹啉-3-羧酸修饰的pargd七肽、其合成、抗血栓活性和应用 |
EP3006454B1 (en) | 2013-06-05 | 2021-01-13 | Shanghai Lumosa Therapeutics Co., Ltd. | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1074438A (zh) * | 1991-11-12 | 1993-07-21 | 伊莱利利公司 | 抗血栓剂 |
CN1477100A (zh) * | 2003-07-14 | 2004-02-25 | �Ϻ���ͨ��ѧ | 一种具有抗血小板聚集活性的化合物及其制备方法 |
-
2006
- 2006-11-30 CN CN200610144236A patent/CN101190895B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1074438A (zh) * | 1991-11-12 | 1993-07-21 | 伊莱利利公司 | 抗血栓剂 |
CN1477100A (zh) * | 2003-07-14 | 2004-02-25 | �Ϻ���ͨ��ѧ | 一种具有抗血小板聚集活性的化合物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
Junmin Huang et al..Efficient resolution of racemic 1,1'-bi-2-naphthol with chiralselectors identified from a small library.Journal of Chromatography A1062.2005,106287-93. * |
JunminHuangetal..Efficientresolutionofracemic1 1'-bi-2-naphthol with chiralselectors identified from a small library.Journal of Chromatography A1062.2005 |
何立文 等.1-(4-酰胺基)苄基四氢异喹啉类化合物的合成与生物活性.药学学报33 11.1998,33(11),864-868. |
何立文 等.1-(4-酰胺基)苄基四氢异喹啉类化合物的合成与生物活性.药学学报33 11.1998,33(11),864-868. * |
Also Published As
Publication number | Publication date |
---|---|
CN101190895A (zh) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101190895B (zh) | N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 | |
US11524977B2 (en) | Ultrasound-assisted simulated digestion method of milk protein active peptide and application thereof in health foods | |
Dakin | On amino-acids | |
Amino et al. | Structure–CaSR–activity relation of kokumi γ-glutamyl peptides | |
AU2008249287B2 (en) | Low-fat food | |
JP6480865B2 (ja) | 新規なα4β7ペプチド二量体拮抗薬 | |
TWI295996B (en) | Dipeptide derivatives | |
Bradshaw et al. | Comparison of Myoglobins from Harbor Seal, Porpoise, and Sperm Whale: V. THE COMPLETE AMINO ACID SEQUENCES OF HARBOR SEAL AND PORPOISE MYOGLOBINS | |
JP2017161529A (ja) | 高感度膵液検出用蛍光プローブ、及び膵液検出方法 | |
JPH06340691A (ja) | ペプチド類 | |
JPH09512806A (ja) | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物(ii) | |
FR2497799A1 (fr) | Sulfate de d-phenylalanyl-l-prolyl-l-arginine aldehyde et procede pour le preparer | |
DK2697246T3 (en) | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF | |
CA2621847A1 (en) | Prodrugs of t3 and t4 with enhanced bioavailability | |
Rodriguez et al. | Synthesis and biological activities of pseudopeptide analogs of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds | |
CA1315041C (en) | Methods and compositions for preparation of the tetrapeptide, alpha-t-x-omega-u-z-y-tyr-r' | |
EP2021353A2 (en) | Peptide substance revealing a stress protective effect, pharmaceutical composition on its base and the method of its application | |
TWI507137B (zh) | Lanthionine derivatives | |
JPS61100594A (ja) | ペプチド化合物 | |
JPS61112099A (ja) | 新規ポリペプチド及びその製造法 | |
CN102120727B (zh) | N-[(3s)-n-氨基酰-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用 | |
CN103450343A (zh) | 四氢异喹啉-3-羧酸修饰的targd七肽、其合成、抗血栓活性和应用 | |
EP1803731A1 (en) | Method of producing partial peptide of enolase protein from plasmodium falciparum | |
TWI407916B (zh) | 濃郁味道(kokumi)賦予劑 | |
JPH0223849A (ja) | ペプチド含有栄養輸液組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100526 Termination date: 20131130 |